AnaBiosCorporation will deploy assays and develop databases for the testing of efficacy and safety of drugs in development. This novel platform will create a paradigm shift in the pharmaceutical industry by providing relevant data in advance of clinical trials, further enabling decision making concerning compound selection, dosing, risk mitigation and management. These studies at AnaBios will allow pharmaceutical companies to efficiently advance their drug development programs with a greater degree of certainty at a fraction of the cost and time compared to current development paradigms.